The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Abstract
Purpose: The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma–related renal impairment (RI). Methods: Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations: All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For the management of RI in patients with multiple myeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lenalidomide should be given with close monitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m 2 to 140 mg/m 2) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance > 15 mL/min, whereas ixazomib in combination with lenalidomide and dexamethasone can be safely administered to patients with creatinine clearance > 30 mL/min (grade A).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationEstimating glomerular filtration rate from serum creatinine and cystatin C
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114248 · Cited by 4,102
Levey, A. S., Eckardt, K.-U., Tsukamoto, Y., Levin, A., Coresh, J., Rossert, J., Zeeuw, D. D. E., Hostetter, T. H., Lameire, N., & Eknoyan, G. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00365.x · Cited by 3,946
Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210
Self-citationMolecular Mechanisms of Amyloidosis
Merlini, G., & Bellotti, V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023144 · Cited by 1,920
Self-citationDimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00464-7 · Cited by 857
Self-citationMichels, W. M., Grootendorst, D. C., Verduijn, M., Elliott, E. G., Dekker, F. W., & Krediet, R. T. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06870909 · Cited by 664
Augustson, B. M., Begum, G., Dunn, J. A., Barth, N. J., Davies, F., Morgan, G., Behrens, J., Smith, A., Child, J. A., & Drayson, M. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2086 · Cited by 488
Diagnosis of monoclonal gammopathy of renal significance
Bridoux, F., on behalf of the International Kidney and Monoclonal Gammopathy Research Group, Leung, N., Hutchison, C. A., Touchard, G., Sethi, S., Fermand, J.-P., Picken, M. M., Herrera, G. A., Kastritis, E., et al. (2015) · Kidney International · doi:10.1038/ki.2014.408 · Cited by 426
Self-citationDimopoulos, M. A., Terpos, E., Chanan-Khan, A., Leung, N., Ludwig, H., Jagannath, S., Niesvizky, R., Giralt, S., Fermand, J.-P., Bladé, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8791 · Cited by 414
Self-citationPalumbo, A., Rajkumar, S. V., San Miguel, J. F., Larocca, A., Niesvizky, R., Morgan, G., Landgren, O., Hajek, R., Einsele, H., Anderson, K. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.7934 · Cited by 392
Self-citationBladé, J., Fernández-Llama, P., Bosch, F., Montolíu, J., Lens, X. M., Montoto, S., Cases, A., Darnell, A., Rozman, C., & Montserrat, E. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.17.1889 · Cited by 383
Renal failure in multiple myeloma: reversibility and impact on the prognosis
Knudsen, L. M., Hjorth, M., Hippe, E., & Nordic Myeloma Study Group (2000) · European Journal of Haematology · doi:10.1034/j.1600-0609.2000.90221.x · Cited by 380
Terpos, E., Morgan, G., Dimopoulos, M. A., Drake, M. T., Lentzsch, S., Raje, N., Sezer, O., García-Sanz, R., Shimizu, K., Turesson, I., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7901 · Cited by 352
Self-citationPlasma Exchange When Myeloma Presents as Acute Renal Failure: A Randomized, Controlled Trial
Clark, W. F., Stewart, A. K., Rock, G. A., Sternbach, M., Sutton, D. M., Barrett, B. J., Heidenheim, A. P., Garg, A. X., Churchill, D. N., & and the Canadian Apheresis Group (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-11-200512060-00005 · Cited by 332
How I treat monoclonal gammopathy of renal significance (MGRS)
Fermand, J.-P., Bridoux, F., Kyle, R. A., Kastritis, E., Weiss, B. M., Cook, M. A., Drayson, M. T., Dispenzieri, A., & Leung, N. (2013) · Blood · doi:10.1182/blood-2013-05-495929 · Cited by 326
Self-citationResults of autologous stem cell transplant in multiple myeloma patients with renal failure
Badros, A., Barlogie, B., Siegel, E., Roberts, J., Langmaid, C., Zangari, M., Desikan, R., Shaver, M. J., Fassas, A., McConnell, S., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03033.x · Cited by 306
Pathogenesis and treatment of renal failure in multiple myeloma
Dimopoulos, M. A., Kastritis, E., Rosinol, L., Bladé, J., & Ludwig, H. (2008) · Leukemia · doi:10.1038/leu.2008.131 · Cited by 305
Self-citationThe pathogenesis and diagnosis of acute kidney injury in multiple myeloma
on behalf of the International Kidney and Monoclonal Gammopathy Research Group, Hutchison, C. A., Batuman, V., Behrens, J., Bridoux, F., Sirac, C., Dispenzieri, A., Herrera, G. A., Lachmann, H., & Sanders, P. W. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.168 · Cited by 289
Johnson, W. J., Kyle, R. A., Pineda, A. A., O'Brien, P. C., & Holley, K. E. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.150.4.863 · Cited by 265
Renal failure in multiple myeloma. Pathogenesis and prognostic implications
Alexanian, R. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.150.8.1693 · Cited by 257
[Renal failure in multiple myeloma].
Sicinski, A. M. (1986) · PubMed · Cited by 223
Jagannath, S., Barlogie, B., Berenson, J. R., Singhal, S., Alexanian, R., Srkalovic, G., Orlowski, R. Z., Richardson, P. G., Anderson, J., Nix, D., et al. (2005) · Cancer · doi:10.1002/cncr.20888 · Cited by 222
Self-citationNasr, S. H., Valeri, A. M., Sethi, S., Fidler, M. E., Cornell, L. D., Gertz, M. A., Lacy, M., Dispenzieri, A., Rajkumar, S. V., Kyle, R. A., et al. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.12.028 · Cited by 213
Self-citationSan-Miguel, J. F., Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2405087 · Cited by 185
Self-citationNONAMYLOIDOTIC MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE
Buxbaum, J., & Gallo, G. (1999) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70123-4 · Cited by 174
Dimopoulos, M. A., Richardson, P. G., Schlag, R., Khuageva, N. K., Shpilberg, O., Kastritis, E., Kropff, M., Petrucci, M. T., Delforge, M., Alexeeva, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2232 · Cited by 172
Self-citationKastritis, E., Anagnostopoulos, Α., Ρούσσου, Μ., Gika, D., Matsouka, C., Barmparousi, D., Grapsa, I., Psimenou, E., Bamias, A., & Dimopoulos, M. A. (2007) · Haematologica · doi:10.3324/haematol.10759 · Cited by 169
Self-citationDimopoulos, M. A., Delimpasi, S., Katodritou, E., Vassou, A., Kyrtsonis, M. C., Repousis, P., Kartasis, Z., Parcharidou, A., Michael, M., Michalis, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt483 · Cited by 161
Self-citationDimopoulos, M. A., Roussou, M., Gkotzamanidou, M., Nikitas, N., Psimenou, E., Mparmparoussi, D., Matsouka, C., Spyropoulou-Vlachou, M., Terpos, E., & Kastritis, E. (2013) · Leukemia · doi:10.1038/leu.2012.182 · Cited by 159
Self-citationCarfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
Badros, A. Z., Vij, R., Martin, T., Zonder, J. A., Kunkel, L., Wang, Z., Lee, S., Wong, A., & Niesvizky, R. (2013) · Leukemia · doi:10.1038/leu.2013.29 · Cited by 153
Ludwig, H., Adam, Z., Hájek, R., Greil, R., Tóthová, E., Keil, F., Autzinger, E. M., Thaler, J., Gisslinger, H., Lang, A. H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1238 · Cited by 149
Self-citationŞengül, Ş., Zwizinski, C. W., Simon, E. E., Kapasi, A. A., Singhal, P. C., & Batuman, V. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00660.x · Cited by 141
Dimopoulos, M. A., Alegre, A. M., Stadtmauer, E. A., Goldschmidt, H., Zonder, J. A., de Castro, C. M., Masliak, Z., Reece, D. E., Olesnyckyj, M., Yu, Z., et al. (2010) · Cancer · doi:10.1002/cncr.25139 · Cited by 137
Self-citationModern Classification of Acute Kidney Injury
Srisawat, N., Hoste, E. A. J., & Kellum, J. A. (2010) · Blood Purification · doi:10.1159/000280099 · Cited by 136
Torrá, R., Bladé, J., Cases, A., López-Pedret, J., Montserrat, E., Rozmán, C., & Revert, L. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb05400.x · Cited by 134
Gonsalves, W. I., Leung, N., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Dingli, D., Kapoor, P., Go, R. S., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.20 · Cited by 133
Self-citationTsakiris, D., Stel, V. S., Finne, P., Fraser, E., Heaf, J. G., Meester, J. D., Schmaldienst, S., Dekker, F. W., Verrina, E. E., & Jager, K. J. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp679 · Cited by 131
Dimopoulos, M. A., Leleu, X. P., Palumbo, A. P., Moreau, P., Delforge, M., Cavo, M., Ludwig, H., Morgan, G. J., Davies, F. E., Sonneveld, P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.60 · Cited by 127
Self-citationSodium Bicarbonate is Associated with an Increased Incidence of Contrast Nephropathy
From, A. M., Bartholmai, B. J., Williams, A. W., Cha, S. S., Pflueger, A. C., & McDonald, F. S. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03100707 · Cited by 127
Scheid, C., Sonneveld, P., Schmidt‐Wolf, I. G. H., van der Holt, B., Jarari, L. E., Bertsch, U., Salwender, H. J., Zweegman, S., Blau, I. W., Vellenga, E., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.087585 · Cited by 127
Self-citationChanging clinical presentation of multiple myeloma
Riccardi, A., Gobbi, P. G., Ucci, G., Bertoloni, D., Luoni, R., Rutigliano, L., & D, E. A. M. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90020-e · Cited by 125
Hutchison, C. A., Heyne, N., Airia, P., Schindler, R., Zickler, D., Cook, M. A., Cockwell, P., & Grima, D. T. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr773 · Cited by 123
Dimopoulos, M. A., Ρούσσου, Μ., Gavriatopoulou, M., Zagouri, F., Migkou, M., Matsouka, C., Barbarousi, D., Christoulas, D., Primenou, E., Grapsa, I., et al. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.n.059 · Cited by 121
Self-citationRenal Improvement in Myeloma with Bortezomib plus Plasma Exchange
Burnette, B. L., Leung, N., & Rajkumar, S. V. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1101834 · Cited by 118
Self-citationOptimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
Dimopoulos, M. A., Palumbo, A. P., Attal, M., Beksaç, M., Davies, F. E., Delforge, M., Einsele, H., Hájek, R., Harousseau, J., da Costa, F. L., et al. (2011) · Leukemia · doi:10.1038/leu.2011.3 · Cited by 118
Self-citationDifferential diagnosis of monoclonal gammopathy of undetermined significance
Merlini, G., & Palladini, G. O. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.595.3798563 · Cited by 117
Self-citationAre myeloma patients with renal failure candidates for autologous stem cell transplantation?
Miguel, J. F. S., Lahuerta, J. J., García‐Sánz, R., Alegre, A. M., Bladé, J., Martínez, R. M. C., García‐Laraña, J., de la Rubia, J., Sureda, A. M., Vidal, M. J., et al. (2000) · The Hematology Journal · doi:10.1038/sj.thj.6200003 · Cited by 116
Tosi, P., Zamagni, E., Cellini, C., Cangini, D., Tacchetti, P., Tura, S., Baccarani, M., & Cavo, M. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00272.x · Cited by 112
Self-citationMDRD Versus CKD-EPI Equation to Estimate Glomerular Filtration Rate in Kidney Transplant Recipients
Masson, I., Flamant, M., Maillard, N., Rule, A. D., Vrtovsnik, F., Péraldi, M., Thibaudin, L., Cavalier, E., Vidal‐Petiot, E., Bonneau, C., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e318288caa6 · Cited by 100
Niesvizky, R., Naib, T., Christos, P. J., Jayabalan, D. S., Furst, J. R., Jalbrzikowski, J., Zafar, F., Mark, T. M., Lent, R. W., Pearse, R. N., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06698.x · Cited by 88
Harris, E., Behrens, J., Samson, D., Rahemtulla, A., Russell, N. H., & Byrne, J. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04395_2.x · Cited by 85
Morabito, F., Gentile, M., Ciolli, S., Petrucci, M. T., Galimberti, S., Mele, G., Casulli, A. F., Mannina, D., Piro, E., Pinotti, G., et al. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01385.x · Cited by 81
Self-citationParikh, G. C., Amjad, A. I., Saliba, R. M., Kazmi, S. M. A., Khan, Z. U., Lahoti, A., Hosing, C. M., Mendoza, F. L., Qureshi, S. R., Weber, D. M., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.03.021 · Cited by 79
Merz, M., Salwender, H., Haenel, M., Mai, E. K., Bertsch, U., Kunz, C., Hielscher, T., Blau, I. W., Scheid, C., Hose, D., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.124347 · Cited by 73 · cited 18×
“1-3 In the era of conventional chemotherapy (CC), RI was associated with a poor median survival time of approximately 2 years.4 The use of novel antimyeloma agents resulted in a substantial increase in the survival of patients withMMwith RI, although, severe RI is associated with as increased risk of early death.5-7 D…”
BackgroundInfluentialSelf-citationΡούσσου, Μ., Kastritis, E., Christoulas, D., Migkou, M., Gavriatopoulou, M., Grapsa, I., Psimenou, E., Gika, D., Terpos, E., & Dimopoulos, M. A. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.04.024 · Cited by 72
Self-citationTerpos, E., Katodritou, E., Tsiftsakis, E., Kastritis, E., Christoulas, D., Pouli, A. G., Michalis, E., Verrou, E., Anargyrou, K., Tsionos, K., et al. (2009) · Haematologica · doi:10.3324/haematol.2008.000638 · Cited by 71
Self-citationDimopoulos, M. A., Christoulas, D., Ρούσσου, Μ., Kastritis, E., Migkou, M., Gavriatopoulou, M., Matsouka, C., Mparmparoussi, D., Psimenou, E., Grapsa, I., et al. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01432.x · Cited by 69
Self-citationMoreau, P., Masszi, T., Grząśko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P. S., Baker, B. W., Jackson, S., et al. (2015) · Blood · doi:10.1182/blood.v126.23.727.727 · Cited by 68
Self-citationKlein, U., Neben, K., Hielscher, T., Heiß, C., Ho, A. D., & Goldschmidt, H. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1080-4 · Cited by 61
Self-citationBladé, J., Sonneveld, P., Miguel, J. F. S., Sutherland, H. J., Hájek, R., Nagler, A., Spencer, A. G., Robak, T., Cibeira, M. T., Zhuang, S. H., et al. (2008) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2008.n.051 · Cited by 59
Self-citationCurrent treatments for renal failure due to multiple myeloma
Gavriatopoulou, M., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1236915 · Cited by 59
Self-citationKhan, R. Z., Apewokin, S. K., Grazziutti, M., Yaccoby, S., Epstein, J., van Rhee, F., Rosenthal, A., Waheed, S., Usmani, S. Z., Atrash, S., et al. (2015) · Leukemia · doi:10.1038/leu.2015.15 · Cited by 52
Terpos, E., Christoulas, D., Kastritis, E., Katodritou, E., Pouli, A. G., Michalis, E., Papassotiriou, I., Dimopoulos, M. A., & Greek Myeloma Study Group (2013) · European Journal Of Haematology · doi:10.1111/ejh.12164 · Cited by 48
Self-citationThalidomide in patients with multiple myeloma and renal failure
Fakhouri, F., Guerraoui, H., Presne, C., Peltier, J., Delarue, R., Muret, P., & Knebelmann, B. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04875.x · Cited by 46
Heyne, N., Denecke, B., Guthoff, M., Oehrlein, K., Kanz, L., Häring, H., & Weisel, K. C. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1383-0 · Cited by 46
Dimopoulos, M. A., Cheung, M. C., Roussel, M., Liu, T., Gamberi, B., Kolb, B., Derigs, H. G., Eom, H., Merzoug, K. B., Lenain, P., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.133629 · Cited by 43
Self-citationMeeting the Unmet Needs in Anticoagulant Therapy
Weitz, J. I. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01461.x · Cited by 42
Pönisch, W., Moll, B., Bourgeois, M., Andrea, M., Schliwa, T., Heyn, S., Schmalfeld, M., Edelmann, T., Becker, C., Hoffmann, F. A., et al. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1513-2 · Cited by 37
Renal Insufficiency and Failure
Dimopoulos, M. A., & Terpos, E. (2010) · Hematology · doi:10.1182/asheducation-2010.1.431 · Cited by 36
Self-citationde la Rubia, J., Roig, M., Ibáñez, Á., García, I., Vera, J. A. E., Aguilar, C., Campo, R. D., González, N., Martínez, R., Palomera, L., et al. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01500.x · Cited by 35
Morabito, F., Gentile, M., Mazzone, C., Rossi, D., Raimondo, F. D., Bringhen, S., Ria, R., Offidani, M., Patriarca, F. F., Nozzoli, C., et al. (2011) · Blood · doi:10.1182/blood-2011-05-353995 · Cited by 35
Self-citationMoreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X. P., Rekhtman, G. B., Masliak, Z., Robak, P. J., Esseltine, D.-L. W., Feng, H., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.118182 · Cited by 35
Self-citationCurrent treatments for renal failure due to multiple myeloma
Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.803068 · Cited by 35
Self-citationTosi, P., Zamagni, E., Tacchetti, P., Ceccolini, M., Perrone, G., Brioli, A., Pallotti, M. C., Pantani, L., Petrucci, A., Baccarani, M., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.02.020 · Cited by 34
Self-citationLenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study
Ludwig, H., Rauch, E., Kuehr, T., Adam, Z., Weißmann, A., Kasparu, H., Autzinger, E.-M., Heintel, D., Greil, R., Poenisch, W., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.115204 · Cited by 30
Self-citationBayraktar, U. D., Warsch, S., & Pereira, D. L. (2010) · American Journal of Hematology · doi:10.1002/ajh.21922 · Cited by 20
Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure
Breitkreutz, I., Heiss, C., Perné, A., Beimler, J., Jäger, D., Egerer, G., Ho, A. D., Neben, K., Zeier, M. G., Goldschmidt, H., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.165 · Cited by 18
Self-citationShi, H., Zhang, W., Li, X., Ren, H., Pan, X., & Chen, N. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.820284 · Cited by 15
Zhou, D.-B., Yu, L., Du, X., Jin, J., Cai, Z., Chen, F., Ke, X., Li, X., Wu, D., Meng, F., et al. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1771-7 · Cited by 13
Cited by
Acute Kidney Injury in Patients with Cancer
Rosner, M. H., & Perazella, M. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1613984 · Cited by 275
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
Rodriguez-Otero, P., van de Donk, N. W. C. J., Pillarisetti, K., Cornax, I., Vishwamitra, D., Gray, K., Hilder, B., Tolbert, J., Renaud, T., Masterson, T., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-023-00966-9 · Cited by 113
Self-citationFacon, T., Venner, C. P., Bahlis, N. J., Offner, F., White, D. J., Karlin, L., Benboubker, L., Rigaudeau, S., Rodon, P., Voog, E., et al. (2021) · Blood · doi:10.1182/blood.2020008787 · Cited by 104
Self-citationHow to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
de Arriba de la Fuente, F., Montes Gaisán, C., & de la Rubia Comos, J. (2022) · Cancers · doi:10.3390/cancers15010155 · Cited by 28
Jurczyszyn, A., & Suska, A. (2019) · Reference Module in Biomedical Sciences · doi:10.1016/b978-0-12-801238-3.11412-6 · Cited by 13
Metadata
- Authors
- Dimopoulos, M. A., Sonneveld, P., Leung, N., Merlini, G., Ludwig, H., Kastritis, E., Goldschmidt, H., Joshua, D., Orlowski, R. Z., Powles, R., Vesole, D. H., Garderet, L., Einsele, H., Palumbo, A., Cavo, M., Richardson, P. G., Moreau, P., San Miguel, J., Rajkumar, S. V., Durie, B. G. M., & Terpos, E.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-05-01
- Volume
- 34
- Issue
- 13
- Pages
- 1544-1557
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2299833483
- Cited by
- 425
- References
- 82
- FWCI
- 32.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.